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Abstract
Heart failure causes significant morbidity and mortality. Distinguishing risk factors for incident
heart failure can help identify at-risk individuals. Orthostatic hypotension may be a risk factor for
incident heart failure; however, this association has not been fully explored, especially in non-
white populations.
The Atherosclerosis Risk in Communities study included 12,363 adults free of prevalent heart
failure with baseline orthostatic measurements. Orthostatic hypotension was defined as a decrease
of systolic blood pressure ≥20 mm Hg or diastolic blood pressure ≥10 mm Hg with position
change from supine to standing. Incident heart failure was identified from hospitalization or death
certificate disease codes.
Over 17.5 years of follow up, orthostatic hypotension was associated with incident heart failure
with multivariable adjustment (hazard ratio 1.54, 95% CI 1.30-1.82). This association was similar
across race and gender groups. A stronger association was identified in younger individuals ≤55
years old (hazard ratio 1.90, 95% CI 1.41-2.55) than in older individuals >55 years old (hazard
ratio 1.37, 95% CI 1.12-1.69, interaction p=0.034).
The association between orthostatic hypotension and incident heart failure persisted with
exclusion of those with diabetes mellitus, coronary heart disease, and those on anti-hypertensives,
psychiatric or Parkinson’s medications. However, exclusion of those with hypertension somewhat
attenuated the association (hazard ratio 1.34, 95% CI 1.00-1.80).
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We identified orthostatic hypotension as a predictor of incident heart failure among middle-aged
individuals, particularly those 45-55 years of age. This association may be partially mediated
through hypertension. Orthostatic measures may enhance risk stratification for future heart failure
development.
Introduction
In 2007, nearly 1,000,000 hospitalizations and over 277,000 deaths in the United States (US)
were related to heart failure (HF).1, 2 Over the past three decades in the US, HF prevalence
has increased to affect 5.8 million people.3, 4 Early identification of individuals at risk for
HF is critical to aggressively modify known HF risk factors, including diabetes mellitus
(DM), hypertension, and coronary heart disease (CHD).5-7 Of interest, orthostatic
hypotension (OH), has been associated with an increased risk for hypertension,8 CHD,9, 10
and mortality.9, 11, 12 Orthostasis has recently been implicated in HF development in two
subgroups of a cohort study in elderly Dutch: those with DM and those in the oldest age
group (78 years (mean), range 71-99 years).9 In addition, a recent cohort study in middle-
aged Swedish adults (age range 26-61 years) found an association between OH and incident
HF that attenuated somewhat after adjustment for traditional HF risk factors.13
Prior studies of the association between OH and HF have largely been in white populations
and older individuals. In addition, medications known to cause OH such as anti-
hypertensive, Parkinson’s and psychiatric medications have not frequently been included in
prior analyses. Thus, we sought to evaluate whether OH is associated with incident clinical
HF in middle-aged white and African-American participants in the Atherosclerosis Risk in
Communities (ARIC) study; we also sought to further evaluate the contribution of specific
medications and known HF risk factors to this relationship. We hypothesized that OH in
middle-aged adults would be associated with incident HF, and that this association would be
robust to exclusion of those with HF risk factors at baseline (DM, hypertension, and CHD),
individuals taking psychiatric or Parkinson’s disease medications, and individuals taking
anti-hypertensives that have been previously associated with OH. We also investigated age
as an effect modifier of this association.
Methods
Study population
The Atherosclerosis Risk in Communities (ARIC) Study is an ongoing longitudinal
population-based study of men and women aged 45-64 at enrollment from 4 U.S.
communities: Jackson, Mississippi; Washington County, Maryland; eight northern suburbs
of Minneapolis, Minnesota; and Forsyth County, North Carolina. The racial distribution in
the Maryland and Minneapolis communities were representative of the area, whereas
African-Americans were oversampled in Forsyth County (15%) and exclusively sampled in
Jackson. There was a 46% response to participate in the initial examination in Jackson and
between 65-67% response for the other sites. The Institutional Review Boards from each site
approved the ARIC study and informed consent was obtained from all participants. The
ARIC study design and rationale, and a comparison between responders and non-responders,
has been previously published.14, 15
From the 15,792 baseline examinees, we excluded race groups other than African-American
or white as well as African-Americans in Minneapolis and Washington county (n=89).
Postural blood pressure (BP) measurements used to define OH were performed at baseline
examinations between 1987-1989. We excluded those with missing data for seated BP (n=3)
and those missing OH measures (n=2,376). Most missing OH measures were from
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participants enrolled in the first 6 months of the study, prior to implementation of postural
BP measurement. We also excluded individuals with atrial fibrillation on 2-minute rhythm
strip at baseline (n=29) and those with prevalent HF (n=606) and/or missing information
that precluded the determination of prevalent HF (n=213) at baseline. Those with prevalent
HF were excluded from this analysis by the following criteria: (1) answering “yes” when
asked “Were any of the medications you took during the last 2 weeks for heart failure?” or
(2) stage 3 or “manifest HF” by Gothenburg criteria.16 The remaining 12,363 participants
were included in this study.
Orthostatic Hypotension Definition
At baseline examination, a Dinamap 1846 SX oscillometric device was utilized to ascertain
supine and standing BP measurements with a standardized protocol. Supine BP
measurement followed an approximately 20-minute supine ultrasound examination;
measurements were taken at 30 second intervals for 2 minutes (range of 2 to 5
measurements). Participants then stood upright and a standing BP measurement was taken as
their feet touched the ground. Standing BP measurements continued at 30 second intervals
for 2 minutes (range of 2 to 5 measurements). OH was defined as a decrease in systolic BP ≥
20 mmHg or a decrease in diastolic BP ≥ 10 mmHg when the average supine BP was
compared to the average standing BP after exclusion of the first standing BP
measurement.12, 17 OH was identified in 612 individuals at the baseline examination.
Ascertainment of incident heart failure
Incident HF cases were accrued through 2008 (mean 17.5 years of follow-up) and were
ascertained through annual contacts and review of ICD codes from hospitalizations and
death certificates. Incident HF (N=1,720) was defined as the first occurrence of either: 1)
Hospital ICD-9 ‘428.x’ (in any position in the diagnosis codes), or 2) ICD-9 ‘428’or ICD-10
‘I50’ listed on a death certificate (in any position in the diagnosis codes). In HF cases
defined by hospitalization with a HF diagnosis, the date of admission was used to define the
date of incident HF.
Covariate definitions
All covariate measurements were obtained at baseline. Age, gender, race, educational level,
alcohol use, medication use, and smoking status were obtained by self-report from the
baseline questionnaire. Height and weight were measured by technicians; body mass index
was calculated as weight (kilograms) divided by height squared (meters2). A history of CHD
included prior myocardial infarction (defined by either self-report of physician-diagnosed
myocardial infarction or by silent myocardial infarction as identified by
electrocardiography) or a prior coronary revascularization procedure or coronary artery
bypass surgery. Left ventricular hypertrophy was identified by electrocardiography using
Cornell criteria.18 DM was defined as any of the following: self-reported history of
physician-diagnosed DM, recent use of medication for DM, fasting blood glucose
concentration ≥ 126 mg/dL, or non-fasting blood glucose concentration ≥ 200 mg/dL.
Methods for the measurement of blood levels of glucose have been previously described.19
Standardized methodology was used to measure BP and resting heart rate, as previously
described.15 Hypertension was defined as either resting seated systolic BP ≥140 mm Hg or
diastolic BP ≥ 90 mm Hg or recent use of antihypertensive medications. Seated BP was
measured at the beginning of the baseline examination following a five minute resting
period; BP values were the average of the second and third measurements.15
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We modeled the relationship between OH and time to incident HF using multivariable Cox
proportional hazards regression. Log negative log survival curves and time interaction tests
were used to evaluate the proportional hazard assumption for OH and all covariates. Models
were adjusted for all above covariates. Additional models were stratified by age, race, and
gender. In secondary analyses, we excluded those with DM (n=1,236), hypertension
(n=3,807), CHD (n=414), those taking psychiatric or Parkinson’s disease medications
(n=726), those taking anti-hypertensives including Angiotensin-Converting Enzyme (ACE)
inhibitors, diuretics, and beta-blockers (n=2,758) and those who were censored or developed
HF (n=175) in the first two years of the study. Calcium channel blockers were not included
in the medication analysis due to less frequent association with OH; clonidine was also not
included in this analysis as no participants were taking this medication at baseline. All
analyses were performed using SAS 9.1 (SAS Institute, Cary, North Carolina).
Results
Those who developed HF during follow up (n=1,720) were more likely to be over 55 years
old, male, African-American, obese, have less than a high school education, and were less
likely to be current alcohol users (Table 1). Known HF risk factors, including DM,
hypertension, and CHD were more common among individuals who developed incident HF.
OH at baseline was 7% more common among those who developed incident HF (11%) than
those who did not (4%). When ACE inhibitor, beta-blocker, and diuretic use were evaluated
among participants with hypertension at baseline, ACE inhibitor use was more common
among those who developed HF than those that did not (13% versus 10%); beta-blocker and
diuretic use did not significantly differ among hypertensives for development of incident
HF. We additionally found that the average supine systolic BP at baseline was
approximately 22 mm Hg higher in those with OH (n = 612, SBP 146 mm Hg, SE 1.0) than
in those without OH (n = 11,751, SBP 124 mm Hg, SE 0.2).
We identified a strong unadjusted association between baseline OH and incident HF (hazard
ratio (HR) 3.02 (95% CI 2.59-3.52, Figure 1). We then adjusted for several covariates
collected at baseline that had the potential to be confounders; we found the association was
somewhat attenuated but still robust (HR 1.54, 95% CI 1.30-1.82, Table 2).
In a secondary age-stratified analysis, we noted a higher hazard ratio for participants <55
years old (HR 1.90, 95% CI 1.41-2.55) compared to those >55 years old (HR 1.37, 95% CI
1.12-1.69; p value = 0.034 for age interaction). In analyses stratified by race and gender,
associations persisted in all groups with no significant variation in magnitude between the
various race and gender groups (Table 2).
In additional secondary analyses excluding participants with baseline DM and CHD, we
found little change in the association between baseline OH and incident HF (Table 2).
However, the association between baseline OH and incident HF was attenuated with
exclusion of those with hypertension at baseline (HR 1.34, 95% CI 1.00-1.80). Yet, the HR
for incident HF was not markedly higher in those with baseline OH and hypertension (HR
1.63, 95% CI 1.33-2.01). We additionally found that excluding individuals taking ACE
inhibitors, beta-blockers, or diuretics at baseline yielded very little change in the association
between OH and HF (HR 1.47, 95% CI 1.17-1.85). Neither exclusion of individuals on
psychiatric or Parkinson’s medications at baseline nor exclusion of HF cases occurring
during the first two years of follow up yielded a substantial change in the association
between OH and incident HF (Table 2).
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In a population-based cohort of white and black middle-aged adults, we found a significant
association between OH and incident HF that was robust to adjustment for multiple HF risk
factors. This association did not differ substantially between groups stratified by sex and
race. Interestingly, we found that the association between OH and HF was stronger for those
ages 45-55 years than for those ages 56-64 years. Prior studies have been limited to largely
white populations, the elderly, and in some cases have lacked information on medications
known to cause OH. Our findings were robust to exclusion of participants with DM, CHD,
those taking psychiatric or Parkinson’s medications, and those taking specific anti-
hypertensives (ACE inhibitors, diuretics, and beta-blockers). However, exclusion of those
with hypertension modestly attenuated the association between OH and HF.
Numerous compensatory mechanisms work to maintain BP immediately following
positional change from supine to upright. The carotid baroreceptor response plays a major
role in this process through increasing sympathetic activity and inhibiting parasympathetic
activity, in turn leading to catecholamine release, vasoconstriction, and increased heart
rate.20-22 Abnormalities in any of these processes can lead to OH.
OH has been observed in patients with DM,23 in whom autonomic neuropathy, a subtype of
diabetic peripheral neuropathy, is the main cause of OH.24 Diabetic autonomic neuropathy
can cause dysfunction of autonomic nerves that regulate cardiac function and vascular
response to positional changes to ultimately result in OH. In addition, insulin has inherent
vasodilatory effects that may contribute to OH in diabetics.25 However, we found that OH
was associated with HF even among individuals without DM at baseline, suggesting that
diabetic autonomic neuropathy was not a substantial contributor to this relationship.
In hypertensive individuals with OH, proposed pathophysiological mechanisms for OH
include impaired baroreceptor responsiveness, increased vascular stiffness related to
arteriosclerosis, presence of left ventricular hypertrophy, and medication-related side
effects.26-29 Anti-hypertensive medications, including diuretics and ACE inhibitors, have
been associated with OH.30 However, certain beta-blockers have been theorized to have
potential pressor effects in elderly, mildly hypertensive patients.31 In our study,
hypertension was defined to include those with elevated BP or reported antihypertensive
medications use at baseline. When participants with hypertension were excluded, the
association between OH and HF attenuated somewhat, which may have been partly related
to loss of statistical power as a large number of participants were excluded from the
analysis. This attenuation was not likely due to the effect of anti-hypertensive medications,
as exclusion of individuals taking ACE inhibitors, diuretics, or beta-blockers at baseline had
little effect on the association between OH and HF. The attenuation may suggest that
hypertension and OH could contribute to incident HF through a similar pathway, such as
through recumbent hypertension, as supine BP was approximately 22 mm Hg higher in
those with OH than in those without OH at baseline. However, it is important to note that
adjusting for supine BP in our overall adjusted model did not eliminate the association
between OH and HF.
While the exact mechanism for OH that precedes HF development is uncertain, we speculate
that early atherosclerotic disease may affect one or more of the previously described
compensatory responses to positional change and manifest as OH prior to HF development.
Furthermore, since many conditions, including hypertension, DM and CHD, are associated
with both OH and HF, such competing factors may facilitate the association between OH
and incident HF (Figure 2).
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To address possible under-ascertainment of prevalent HF at baseline, we performed an
analysis excluding those with a HF hospitalization during the first two years of follow-up,
which yielded very little change in the association between OH and HF. A two-year time
period was selected for this analysis as most prevalent HF cases would likely require
hospital admission over the course of two years.32
Of interest, we found that age was a significant effect modifier of the association between
OH and incident HF; the association was stronger in adults 45-55 years old (HR 2.42, 95%
CI 1.82-3.23) compared to those 56-64 years old (HR 1.70, 95% CI 1.38-2.10). In a Swedish
population-based cohort study, younger adults 26-44 years old with OH also had higher risk
of incident HF [HR 2.43 (95% CI 1.48-3.97)] than older adults 45-61 years old [HR 1.16
(95% CI 0.90-1.48)].13 However, the opposite association with age was found in a
population-based cohort study of elderly Dutch from Rotterdam, in which the strongest
association between OH and incident HF was in the oldest participants (mean 78 years,
range 71-99; HR 1.32, 95% CI 1.04-1.67).9 In this same study, when age was divided into
tertiles, no significant association between OH and incident HF was found in the two
younger age groups (age ranges 55-63 and 63-71 years). In sum, the differential associations
between OH and HF in various age groups are difficult to compare across studies, given that
the Malmo and ARIC studies are in younger cohorts than the Rotterdam study. Yet, these
divergent findings among age groups suggest that separate mechanisms may account for OH
in the elderly compared to younger age groups. Another possibility is that the risk conferred
by OH for incident HF may assume a U shaped age distribution with younger and older
adults at highest risk. In the elderly, OH has been associated with the presence of multiple
comorbidities,9, 25, vascular stiffness, 33 and with baroreflex dysfunction.34, 35 We speculate
that OH in younger, apparently healthy individuals may indicate sub-clinical cardiac
dysfunction and/or vascular stiffness related to atherosclerotic disease. In both elderly and
young, OH has been associated with increased mortality risk.12, 36, 37
Both the Malmo and Rotterdam studies are in predominantly white populations, whereas our
study has both white and African-American participants. As such, we could evaluate effect
modification by race in our study. When stratified by race and gender, we observed that the
hazard ratio associating OH and incident HF was lowest in white men and highest in
African-American men, although the differences noted between race and gender groups
were not statistically significant and confidence intervals overlapped substantially. In
addition, the association between OH and incident HF was not statistically significant in
African-American men, which can be partly attributed to a smaller subgroup sample size.
Our main study limitations were the definitions of prevalent and incident HF. At baseline
examination, no specific question regarding a previous HF diagnosis was asked of
participants. As a result, criteria of self-reported treatment for HF and the Gothenburg HF
criteria were used as a proxy.16 To address potential prevalent HF cases not identified at
enrollment, we performed a secondary analysis as previously discussed. With regard to the
definition of incident HF, because HF was not a formalized outcome when the ARIC study
was initiated, HF diagnostic codes were utilized to define the outcome without physician
review for validation. This may have resulted in under-ascertainment of less severe cases of
HF as only hospital and death certificate codes were used to define this outcome, though
ICD-9 code 428 and ICD-10 code I50 are specific and are the most frequently documented
HF codes.38, 39 Another limitation is the lack of echocardiographic study results to define
HF as systolic or diastolic. However, similar readmission and mortality rates have been
found in HF patients with ejection fractions of >40% compared to ejection fractions of
<40%.40 Another limitation was that we were unable to evaluate OH at follow up visits as
OH measures were only available from the baseline examination. Finally, hypertension was
defined either through multiple measurements taken at the baseline visit or by report of
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taking antihypertensive medications, which may have over-estimated the number of
participants with prevalent hypertension and affected our secondary analysis of this
population.
The strengths of this study include its prospective design and long-term follow-up of a large,
well-characterized, white and African-American cohort. Furthermore, this is the first cohort
study to evaluate the relationship between OH and incident HF in both white and African-
American participants. Compared to prior evaluations of OH and incident HF, we performed
secondary analyses to evaluate known HF risk factors and medications that are known to
cause OH.
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Implications from our study are that OH appears to be associated with incident HF,
which is somewhat attenuated with the exclusion of participants with hypertension. We
found a stronger association between OH and HF in younger adults than in older adults.
Given our findings, we speculate that OH preceding HF may be a marker of early sub-
clinical atherosclerosis that is facilitated by hypertension and potentially by other risk
factors to contribute to HF development.
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- The association between OH and incident HF did not vary greatly among white and
African-American participants.
- A stronger association between OH and HF was identified in younger (ages 45-55)
compared to older adults (ages 56-64).
What Is Relevant?
- The association between OH and HF may be partially explained by hypertension;
we speculate that recumbent hypertension may also contribute to this association.
- Medications for hypertension do not appear to play a large role in the OH and HF
association.
Summary
- OH appears to be associated with HF development; the strength of this relationship
is not as strong when participants with hypertension were excluded from the
analysis.
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Unadjusted Kaplan-Meier Survival Plot: Time to Incident HF, Stratified by Presence or
Absence of Orthostatic Hypotension at Baseline Examination, the ARIC study (1987-2008)
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Demonstrating Theory of Competing Factors for Association Between Orthostatic
Hypotension and Incident Heart Failure
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Table 1
Characteristics of the Atherosclerosis Risk in Communities (ARIC) Population (N = 12,363) at Baseline
(1987-1989) by Development of Incident HF
Characteristics Incident HF(N = 1,720
No Incident HF
(N = 10,643)
Age > 55 years, %* 60 38
Male, %* 53 44
African American, %* 35 25
BMI >30, %* 40 24
Study Center, %*
 Jackson, MS 31 22
 Forsyth County, NC 24 27
 Minneapolis, MN 17 27
 Washington County, MD 28 24
Less than high school education, %* 38 20
Current smoker, %* 36 24
Current alcohol use, %* 46 59
Parkinson’s or Psychiatric Medications, %* 8 6
Diabetes Mellitus, %* 29 8
Mean Supine Systolic BP, mm Hg (SE)* 136 (0.6) 123 (0.2)
Mean Heart Rate, beats per minute (SE)* 69 (0.3) 66 (0.1)
Left Ventricular Hypertrophy, %* 6 2
Coronary Heart Disease, %* 13 3
Orthostatic Hypotension, %* 11 4
Hypertension, %* 53 29






Percents among participants with hypertension
‡
p value = 0.006 among participants with hypertension
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Table 2
Association of Baseline Orthostatic Hypotension with Incident HF, Stratified by Age, Race/Gender and







Unadjusted 12,363 3.02 (2.59-3.52)
Overall adjusted* 11,743 1.54 (1.30-1.82)
Age-stratified analysis †
 Age ≤55 years 6,868 1.90 (1.41-2.55)
 Age >55 years 4,875 1.37 (1.12-1.69)
Race and gender stratified analysis †
 White Women 4,528 1.59 (1.13-2.23)
 African-American Women 1,885 1.60 (1.14-2.24)
 White Men 4,155 1.31 (1.00-1.72)
 African-American Men 1,175 1.71 (0.98-2.99)
Secondary Analyses with Exclusions
Exclusion of diabetes at baseline† 10,507 1.50 (1.22-1.84)
Exclusion of hypertension at baseline† 7,936 1.34 (1.00-1.80)
Exclusion of individuals on anti-
hypertensives (ACE inhibitors, beta-
blockers or diuretics) at baseline†
9,111 1.47 (1.17-1.85)
Exclusion of CHD at baseline† 11,329 1.52 (1.27-1.82)
Exclusion of psychiatric or Parkinson’s
medications at baseline†
11,017 1.43 (1.19-1.72)
Exclusion of HF cases from first 2 years
of follow-up†
11,568 1.60 (1.35, 1.90)
*
Models adjusted for baseline variables: age, gender, race by center, body mass index, educational level, smoking, alcohol use, diabetes mellitus,
mean supine systolic blood pressure, resting heart rate, left ventricular hypertrophy, coronary heart disease, and hypertension
†
For secondary analyses, all of the above covariates were adjusted for except the stratified covariates
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